Livagen (50mg)

What is Livagen (50mg)?

Livagen (50mg) is a synthetic tetrapeptide (Lys‑Glu‑Asp‑Ala), classified as an organ‑specific peptide bioregulator. It is primarily studied for its impact on chromatin organization and gene accessibility in differentiated cells.

In laboratory research, Livagen serves as a defined tool to investigate how short peptides influence chromatin structure, transcriptional accessibility, and ribosomal gene activity. It is commonly used in lymphocyte-based models and liver-associated systems to study gene expression and nucleolar function, strictly within preclinical contexts.

Product Specifications

• Synonyms: Livagen; KEDA tetrapeptide; liver peptide bioregulator; Lys‑Glu‑Asp‑Ala peptide​​
• Peptide Sequence: H‑Lys‑Glu‑Asp‑Ala‑OH (Lys‑Glu‑Asp‑Ala)​​
• Chemical Formula: C₁₈H₃₁N₅O₉​
• Molecular Weight: 461.46 g/mol
• CAS Number: 195875‑84‑4​
• Purity: Supplied as a high‑purity, research‑grade peptide; identity and purity are typically confirmed by HPLC and mass spectrometry, with lot‑specific values documented in the accompanying certificate of analysis (COA).​
• Packaging Format: 50 mg lyophilized (freeze‑dried) peptide in a sealed laboratory vial, intended for reconstitution with an appropriate solvent or buffer before use.
• Storage Conditions: Store at −20°C, protected from light and moisture; avoid repeated freeze–thaw cycles to help maintain peptide integrity.​
• Intended Use: For laboratory research use only; not for human or veterinary use.

Key Characteristics of Livagen (50mg)

• Chromatin-focused bioregulator: Researchers study KEDA for its potential to affect chromatin packing and gene accessibility in differentiated cells.
• Lymphocyte model use: Commonly used in lymphocyte systems to track chromatin decondensation and shifts between heterochromatin and euchromatin
• Nucleolar and ribosomal readouts: Studies often monitor nucleolar activity and ribosomal gene transcription as indicators of transcriptional activation.
• Gene-expression profiling: Research frequently evaluates changes in mRNA patterns linked to immune-related and metabolic pathways.

How Livagen (50mg) Supports Research

Livagen (50mg) supports research by providing a well-defined tetrapeptide for studying how chromatin organization influences transcriptional regulation and ribosomal gene activation.

In lymphocyte-based models and liver-associated systems, Livagen allows researchers to explore how short peptides modulate gene accessibility and nucleolar function. Its ability to influence chromatin decondensation and transcriptional output makes it a practical tool for investigating epigenetic mechanisms and gene expression regulation in differentiated cells.

Research Applications & Usage Information

• Chromatin State and Nuclear Organization: Used in lymphocyte models to evaluate heterochromatin/euchromatin balance, decondensation markers, and NOR-related activity as indicators of chromatin activation.
• Ribosomal Gene Activity and Protein Synthesis: Applied in studies that track ribosomal transcription and nucleolar readouts (including Ag-NOR–based assays) as proxies for cellular transcriptional activity.
• Peptide Regulation of Gene Expression: Included in broader programs examining how short peptides relate to gene-expression patterns, including immune and metabolic signaling networks.
• Enzyme Activity and Peptide Turnover Studies: Used in assays that look at peptide stability, turnover, and peptidase-related activity under defined conditions.
• Neuroimmune and Gastrointestinal Model Systems: Applied in select immune-tissue and GI-related systems to explore chromatin remodeling and gene-regulation endpoints in preclinical research.

Handling and Storage Recommendations

• Keep lyophilized vials at −20°C or colder, dry, and protected from light.
• Let the sealed vial reach room temperature to reduce condensation.
• Use a sterile solvent or buffer suited to your assay. Split into small, labeled portions to limit freeze–thaw cycles.
• Refrigerate or freeze based on your lab’s stability guidance; discard if appearance changes or beyond validated timelines.
• Use standard PPE and dispose of materials in accordance with institutional waste procedures.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in‑vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Khavinson VKh, Lezhava TA, Monaselidze JG, et al. Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People. Bulletin of Experimental Biology and Medicine. 2002;134(4):389-392. doi:10.1023/a:1021924702103
2. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053
3. Lezhava T, Jokhadze T, Monaselidze J, et al. EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE “OLD” CHROMATIN. PubMed. Published February 1, 2023. https://pubmed.ncbi.nlm.nih.gov/37042594/
4. Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clinical Epigenetics. 2019;11(1):101. doi:10.1186/s13148-019-0700-7
5. Khavinson VKh, Lin’kova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine. 2016;162(2):288-292. doi:10.1007/s10517-016-3596-7